MyBioSource

antibody

Rabbit Polyclonal to Human NEU1 / NEU

MBS240546

0.05 ml

495 USD

polyclonal

rabbit

human

western blot, immunohistochemistry, immunocytochemistry

MBS240546

Antibody

Rabbit Polyclonal to Human NEU1 / NEU

NEU1 / NEU

Anti-NEU1 / NEU Antibody (N-Terminus) IHC-plus; NEU1; Acetylneuraminyl hydrolase; G9 gene encoding sialidase; G9 sialidase; Exo-alpha-sialidase; Neu; Sialidase-1; Lysosomal sialidase; SIAL1; N-acetyl-alpha-neuraminidase 1; NANH; Human NEU1; NEU

sialidase-1; Sialidase-1; sialidase-1; G9 sialidase; exo-alpha-sialidase; lysosomal sialidase; acetylneuraminyl hydrolase; N-acetyl-alpha-neuraminidase 1; sialidase 1 (lysosomal sialidase); Acetylneuraminyl hydrolase; G9 sialidase; Lysosomal sialidase; N-acetyl-alpha-neuraminidase 1

NEU1

NEU

NEU1; NEU1; NEU; NANH; SIAL1; NANH

NEUR1_HUMAN

Polyclonal

Rabbit

Human

415

Bacterially expressed and purified fusion protein excluding the signal peptide (first 45 amino acids) and the first 6 N-terminal amino acids of the processed form of human lysosomal neuraminidase.

Sterile filtered

0.02 M potassium phosphate, 0.15 M sodium chloride, pH 7.2, 0.1% sodium azide.

85 mg/ml

+4 degree C or -20 degree C, Avoid repeated freezing and thawing.

Immunohistochemistry (IHC - Paraffin), Immunofluorescence (IF), Western Blot (WB)

IF (1:500), IHC-P (1:500), WB (1:500). Usage: Immunohistochemistry: was validated for use in immunohistochemistry on a panel of 21 formalin-fixed, paraffin-embedded (FFPE) human tissues after heat induced antigen retrieval in pH 6.0 citrate buffer. After incubation with the primary antib.

Target Species: Human. Immunogen Description: Fusion protein from human NEU1.

Immunogen: NEU1 / NEU antibody was raised against fusion protein from human NEU1. Antigen Modification: N-Terminus

NEU encodes the lysosomal enzyme neuraminidase, which cleaves terminal sialic acid residues from substrates such as glycoproteins and glycolipids. In the lysosome, neuraminidase is part of a heterotrimeric complex together with beta-galactosidase and cathepsin A (the latter also referred to as 'protective protein'). Mutations in NEU that interfere with neuraminidase enzymatic activity can lead to sialidosis.

4557791

NP_000425.1

NM_000434.3

Q99519

45,467 Da

Asparagine N-linked Glycosylation Pathway 161013!!Biosynthesis Of The N-glycan Precursor (dolichol Lipid-linked Oligosaccharide, LLO) And Transfer To A Nascent Protein Pathway 161014!!Defective ALG1 Causes ALG1-CDG (CDG-1k) Pathway 1127605!!Defective ALG11 Causes ALG11-CDG (CDG-1p) Pathway 1127608!!Defective ALG12 Causes ALG12-CDG (CDG-1g) Pathway 1127601!!Defective ALG14 Causes Congenital Myasthenic Syndrome (ALG14-CMS) Pathway 1127613!!Defective ALG2 Causes ALG2-CDG (CDG-1i) Pathway 1127603!!Defective ALG3 Causes ALG3-CDG (CDG-1d) Pathway 1127599!!Defective ALG6 Causes ALG6-CDG (CDG-1c) Pathway 1127597!!Defective ALG8 Causes ALG8-CDG (CDG-1h) Pathway 1127602

The protein encoded by this gene is a lysosomal enzyme that cleaves terminal sialic acid residues from substrates such as glycoproteins and glycolipids. In the lysosome, this enzyme is part of a heterotrimeric complex together with beta-galactosidase and cathepsin A (the latter is also referred to as 'protective protein'). Mutations in this gene can lead to sialidosis, a lysosomal storage disease that can be type 1 (cherry red spot-myoclonus syndrome or normosomatic type), which is late-onset, or type 2 (the dysmorphic type), which occurs at an earlier age with increased severity. [provided by RefSeq, Jul 2008]

0.05 ml

495 USD